Roche strikes $4.8B deal to acquire Spark Therapeutics

Drug giant Roche will buy gene therapy developer Spark Therapeutics for about $4.8 billion in cash, according to Bloomberg.

Roche will pay $114.50 per share, more than twice Spark's closing price on Feb. 22.

The deal will give Roche access to a gene therapy for blindness priced at $850,000 per patient, as well as other projects for hemophilia and neurodegenerative disorders like Huntington's disease.

Roche's deal comes as other big-name drugmakers pivot to gene therapy.

Read the full report here.

 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like